Information Provided By: 
Fly News Breaks for February 19, 2019
CNMD
Feb 19, 2019 | 07:24 EDT
Barclays analyst Kristen Stewart reinstated coverage of Conmed and upgraded the shares to Overweight with an $85 price target. The analyst says the company's recently reported Q4 results, better than expected 2019 guidance, and the completion of the Buffalo Filter transaction ease her concerns around the sustainability of its growth and 2019 expectations. She views Conmed's current valuation as attractive.
News For CNMD From the Last 2 Days
There are no results for your query CNMD
